Obsidian Therapeutics

Obsidian Therapeutics is a privately held, clinical-stage biotechnology company focused on engineered cell therapies. It is known for its work on "controllable" gene circuits designed to regulate the activity of therapeutic cells after they are administered to patients. Its platform aims to allow clinicians to modulate the expression of therapeutic proteins, such as cytokines, to improve the safety and efficacy of cell therapies. The company operates in the highly specialized field of cell and gene therapy, which combines principles of immunology, synthetic biology, and genetic engineering. Obsidian's approach is intended to address key challenges in adoptive cell therapy, including toxicity management and enhancement of antitumor activity. Although not a household name, the company is among a wave of innovative biotechnology companies working to bring next-generation cell therapies to market. As a private company, Obsidian Therapeutics is backed by venture capital and institutional investors. It has not disclosed a public listing and does not trade on any stock exchange. The company's research and development activities are primarily located in the United States, and it collaborates with academic and clinical partners to advance its pipeline. Specific details about its founding, headquarters, and financial backing are not available in the provided evidence, and the company maintains a relatively low public profile compared with large biopharmaceutical companies.

Obsidian Therapeutics is a privately held biotechnology company that has been developing engineered cell therapies. The company's history is not extensively documented in the provided evidence. It is known to operate in the cell and gene therapy space, focusing on controllable genetic switches to regulate therapeutic cell activity. Specific founding details, such as the year and founders, are not available in the evidence. The company remains active and private, with no public listing.

• 2022.01.19

  Reported2022.01.19

  Maria Fardis succeeds Peter Barrett as Obsidian board chair[1]Maria Fardis接任Obsidian董事会主席prnewswire.com

  Obsidian Therapeutics announced that Maria Fardis had assumed the role of board chair, succeeding Peter Barrett, who would remain on the board.

• 2019.09.24

  Reported2019.09.24

  Obsidian Therapeutics appoints Erin Boyer as VP of Human Resources[2]Obsidian Therapeutics 任命 Erin Boyer 为人力资源副总裁prnewswire.com

  Obsidian Therapeutics announced the appointment of Erin Boyer as Vice President, Human Resources. She will oversee the company's human resources operations and strategy.

Read more

1. 1Maria Fardis接任Obsidian董事会主席prnewswire.com
2. 2Obsidian Therapeutics 任命 Erin Boyer 为人力资源副总裁prnewswire.com
3. 3Obsidian Therapeutics Appoints Anders Götzsche to Board of Directorsprnewswire.com